Ambrx Biopharma receives NYSE non-compliance letter
Ambrx Biopharma introduced that it acquired a discover on November 23, 2022 from the New York Inventory Trade that it was not in compliance with the NYSE’s continued itemizing requirements as a result of the common closing value of Ambrx’s American Depositary Shares, every representing seven abnormal shares, had fallen under $1.00 per ADS over a interval of 30 consecutive buying and selling days, which is the minimal common closing value per ADS required to keep up continued itemizing on the NYSE. In accordance with relevant NYSE procedures, Ambrx is required to subject this press launch and, pursuant to the itemizing necessities, has additionally submitted a response letter outlining its plan to treatment the deficiency.
Revealed first on TheFly
See the highest shares advisable by analysts >>
Learn Extra on AMAM: